Susquehanna International Group
OTLKW

Susquehanna International Group’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Susquehanna International Group’s Portfolio OTLKW Stock Details OTLKW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,798
Closed -$4K – 14570
2021
Q4 		$4K Sell
30,798
-48,061
-61% -$8.4K ﹤0.01% 12999
2021
Q3 		$16K Sell
78,859
-51,981
-40% -$14.1K ﹤0.01% 12578
2021
Q2 		$41K Buy
+130,840
New +$64K ﹤0.01% 12338
2020
Q4 		– Sell
-22,156
Closed -$3K – 11982
2020
Q3 		$3K Buy
22,156
+2,086
+10% +$397 ﹤0.01% 10455
2020
Q2 		$6K Buy
+20,070
New +$3.15K ﹤0.01% 10004
2020
Q1 		– Sell
-25,012
Closed -$2K – 11158
2019
Q4 		$2K Sell
25,012
-11,368
-31% -$1.18K ﹤0.01% 9591
2019
Q3 		$4K Buy
36,380
+16,637
+84% +$2.43K ﹤0.01% 10053
2019
Q2 		$2K Buy
+19,743
New +$3.68K ﹤0.01% 10121
2019
Q1 		– Sell
-24,311
Closed -$4K – 10206
2018
Q4 		$4K Buy
+24,311
New +$3.07K ﹤0.01% 8797

Susquehanna International Group's OTLKW Position: Q1 2022 in Review

Susquehanna International Group sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q1 2022, closing a stake of 30,798 shares — an estimated $4K sold.

Susquehanna International Group first reported a position in OTLKW in Q4 2018 and held it in 9 quarters. The position peaked at $41K in Q2 2021. 0 funds tracked by Wall St. Rank hold OTLKW as of Q1 2022.

  • Susquehanna International Group reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q1 2022 after selling out during the quarter.
  • Susquehanna International Group sold 30,798 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q1 2022, an estimated $4K.
  • Susquehanna International Group first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q4 2018 and held it in 9 quarters.
  • Susquehanna International Group's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $41K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.